Intravacc, a global contract development and manufacturing organization (CDMO) specializing in infectious disease and therapeutic vaccines, and Primrose Bio, a biotechnology company with technologies that improve the manufacturing of next-generation therapeutics, have partnered to enhance the development and supply of conjugate vaccines.
 
This partnership aims to harness the strengths of both companies. Intravacc contributes its technical expertise, facilities, and capabilities in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines.
 
Meanwhile, Primrose Bio complements this with its ultra-pure production, supply chain, and regulatory support for the PeliCRM197 carrier protein, a vital ingredient in conjugate vaccine formulations and the only commercial CRM197 used in commercial vaccines available for purchase.
 
The partnership signifies a strategic alignment aimed at advancing vaccine development and accessibility for researchers and industry clients. Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.
 
Dr. Jan Groen, Intravacc’s CEO, says: “We are excited to announce our partnership with Primrose Bio. By combining our expertise with Primrose’s cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide.”
 
Dr. Helge Zieler, Primrose Bio’s CEO, comments: “Expanding the capability of our PeliCRM197 franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development. With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole.”